Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease.

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Visca, D.
  • Centis, R.
  • Pontali, E.
  • Zampogna, E.
  • Russell, A. -M.
  • Migliori, G. B.
  • Andrejak, C.
  • Aro, M.
  • Bayram, H.
  • Berkani, K.
  • Bruchfeld, J.
  • Chakaya, J. M.
  • Chorostowska-Wynimko, J.
  • Crestani, B.
  • Dalcolmo, M. P.
  • D'Ambrosio, L.
  • Dinh-Xuan, A-T.
  • Duong-Quy, S.
  • Fernandes, C.
  • Garcia-Garcia, J. -M.
  • de Melo Kawassaki, A
  • Carrozzi, L.
  • Martins, P. Carreiro
  • Mirsaeidi, M.
  • Mohammad, Y.
  • Naidoo, R. N.
  • Neuparth, N.
  • Sese, L.
  • Silva, D. R.
  • Solovic, I.
  • Sooronbaev, T. M.
  • Spanevello, A.
  • Sverzellati, N.
  • Tanno, L.
  • Tiberi, S.
  • Vasankari, T.
  • Vasarmidi, E.
  • Vitacca, M.
  • Annesi-Maesano, I.

Grupos

Abstract

BACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice' care for the diagnosis, treatment and prevention of post-COVID-19 lung disease.METHODS: A panel of international experts representing scientific societies, associations and groups active in post-COVID-19 lung disease was identified; 45 completed a Delphi process. A 5-point Likert scale indicated level of agreement with the draft standards. The final version was approved by consensus (with 100% agreement).RESULTS: Four clinical standards were agreed for patients with a previous history of COVID-19: Standard 1, Patients with sequelae not explained by an alternative diagnosis should be evaluated for possible post-COVID-19 lung disease; Standard 2, Patients with lung function impairment, reduced exercise tolerance, reduced quality of life (QoL) or other relevant signs or ongoing symptoms =4 weeks after the onset of first symptoms should be evaluated for treatment and pulmonary rehabilitation (PR); Standard 3, The PR programme should be based on feasibility, effectiveness and cost-effectiveness criteria, organised according to local health services and tailored to an individual patient's needs; and Standard 4, Each patient undergoing and completing PR should be evaluated to determine its effectiveness and have access to a counselling/health education session.CONCLUSION: This is the first consensus-based set of clinical standards for the diagnosis, treatment and prevention of post-COVID-19 lung disease. Our aim is to improve patient care and QoL by guiding clinicians, programme managers and public health officers in planning and implementing a PR programme to manage post-COVID-19 lung disease.

Datos de la publicación

ISSN/ISSNe:
1027-3719, 1815-7920

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE  INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)

Tipo:
Article
Páginas:
729-741
PubMed:
37749839
Factor de Impacto:
0,845 SCImago
Cuartil:
Q2 SCImago

Documentos

  • No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Keywords

  • long COVID; SARS-COV-2; post-COVID conditions; pulmonary rehabilitation; quality of life

Campos de Estudio

Proyectos y Estudios Clínicos

INTENSIFICACION DR. MIGUEL MARTINEZ GARCIA

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

INT11/037 . 2012

ASOCIACION ENTRE TRASTORNOS RESPIRATORIOS DEL SUEÑO Y TASA DE CRECIMIENTO DEL MELANOMA CUTANEO

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI12/01363 . INSTITUTO DE SALUD CARLOS III . 2013

EFECTO DEL TRATAMIENTO CON CPAP SOBRE LAS CIFRAS TENSIONALES EN PACIENTES CON HIPERTENSION ARTERIAL REFRACTARIA. ESTUDIO MULTICENTRICO Y ALEATORIZADO. ESTUDIO HIPARCO

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI09/01647 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010

INTENSIFICACION DR. MIGUEL ANGEL MARTINEZ GARCIA

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

INT14/00003 . INSTITUTO DE SALUD CARLOS III . 2015

ASOCIACIÓN ENTRE LOS TRASTORNOS RESPIRATORIOS DEL SUEÑO Y EL PRONÓSTICO DEL MELANOMA. ESTUDIO LONGITUDINAL Y MULTICÉNTRICO EN 443 PACIENTES CON MELANOMA CUTÁNEO MALIGNO.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI16/01772 . INSTITUTO DE SALUD CARLOS III . 2017

P4COPD: Prediction, Prevention, Personalized and Precision management of COPD in young adults.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PMP21/00090 . INSTITUTO DE SALUD CARLOS III . 2022

Registro nacional de antibóticos inhalados en patología crónica de la vía área.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

REPAIR . 2023

Compartir